Results 21 to 30 of about 4,593,278 (410)

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)

Frontiers in Oncology, 2023
BackgroundThe emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in the treatment landscape of non-small cell lung cancer (NSCLC).
Qin Wang, Chen Qi, Jing Luo, Nan Xu, Mao-tian Xu, Yong Qiang, Chi Zhang, Yi Shen   +7 more
doaj   +1 more source

Neoadjuvant Therapy for Locally Advanced Esophageal Cancers

Frontiers in Oncology, 2022
Esophageal carcinoma is one of the most aggressive malignant diseases. At present, neoadjuvant chemotherapy and neoadjuvant chemoradiotherapy are regarded as the standard modalities for the treatments of locally advanced esophageal cancers based on ...
Runkai Huang, Zhenbin Qiu, Chunwen Zheng, Ruijie Zeng, Wanxian Chen, Simeng Wang, Enmin Li, Yiwei Xu, Yiwei Xu   +8 more
doaj   +1 more source

Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer

Frontiers in Pharmacology, 2023
Whether neoadjuvant therapy confers a survival benefit in advanced prostate cancer (PCa) remains uncertain. The primary endpoints of previous retrospective and phase II clinical studies that used neoadjuvant therapy, including androgen deprivation ...
Yongbao Wei, Yongbao Wei, Ruochen Zhang, Ruochen Zhang, Dewen Zhong, Zhensheng Chen, Gen Chen, Minggen Yang, Le Lin, Le Lin, Tao Li, Tao Li, Liefu Ye, Liefu Ye, Lili Chen, Lili Chen, Qingguo Zhu, Qingguo Zhu   +17 more
doaj   +1 more source

Case report: Major pathologic response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with stage IIIA lung adenocarcinoma harboring BRAF V600E-mutation

Frontiers in Oncology, 2022
Targeted therapy has achieved great success in advanced non-small lung cancer (NSCLC) with driver genes, and neoadjuvant-targeted therapy is increasingly being investigated.
Chaoyuan Liu, Min Lu, Yang Yang, Xiang Wang, Fang Ma, Xianling Liu   +5 more
doaj   +1 more source

Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial.

JAMA Oncology, 2021
Importance Total neoadjuvant therapy has been increasingly adopted for multimodal rectal cancer treatment. The optimal sequence of chemoradiotherapy (CRT) and chemotherapy needs to be established.
E. Fokas, A. Schlenska-Lange, B. Polat, G. Klautke, G. Grabenbauer, R. Fietkau, T. Kuhnt, L. Staib, T. Brunner, A. Grosu, S. Kirste, L. Jacobasch, M. Allgäuer, M. Flentje, Christoph‐Thomas Germer, R. Grützmann, G. Hildebrandt, M. Schwarzbach, W. Bechstein, H. Sülberg, T. Friede, J. Gaedcke, M. Ghadimi, R. Hofheinz, C. Rödel   +24 more
semanticscholar   +1 more source

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression

Frontiers in Oncology, 2022
IntroductionNeoadjuvant trastuzumab plus chemotherapy may affect programmed death-ligand 1 (PD-L1) expression and tumor-infiltrating lymphocytes (TILs) in HER2-positive breast cancer.
Mao Shang, Mao Shang, Yajing Chi, Jianbo Zhang, Jin Chang, Hui Yang, Sha Yin, Qiaorui Tan, Xiaochu Man, Huihui Li   +9 more
doaj   +1 more source

The Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer.

The Journal of the National Comprehensive Cancer Network, 2022
The role of neoadjuvant therapy (NAT) for localized breast cancer has evolved tremendously over the past several years. Currently, NAT is the preferred option for high-risk early triple-negative (TN) and HER2-positive (HER2+) breast cancers and is ...
Laura M. Spring, Yael Bar, S. Isakoff
semanticscholar   +1 more source

Total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy for locally advanced rectal cancer: a systematic review and meta-analysis.

The Oncologist, 2021
OBJECTIVE & BACKGROUND Total neoadjuvant therapy (TNT) is a novel approach for locally advanced rectal cancer (LARC), which attempts to deliver both systemic chemotherapy and neoadjuvant chemoradiotherapy prior to surgery.
Shuang Liu, Ting Jiang, Lin Xiao, Shanfei Yang, Qing Liu, Yuan-hong Gao, Gong Chen, W. Xiao   +7 more
semanticscholar   +1 more source

An open, observational, three-arm clinical study of 2–3 cycles of treatment as neoadjuvant therapy in operable locally advanced non-small cell lung cancer: An interim analysis

Frontiers in Immunology, 2022
BackgroundAn open, observational, three-arm clinical study aimed at investigating the efficacy of different neoadjuvant therapies (neoadjuvant immunotherapy with(out) chemotherapy, neoadjuvant chemotherapy, and neoadjuvant targeted therapy) in operable ...
Linping Gu, Xue Wang, Yile Sun, Yunhua Xu, Xiaomin Niu, Ruiying Zhao, Yaxian Yao, Hong Jian, Yuchen Han, Jinwang Wei, Zhiwei Chen, Shun Lu   +11 more
doaj   +1 more source

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

Journal of Clinical Oncology, 2021
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended
L. Korde, M. Somerfield, L. Carey, J. Crews, N. Denduluri, E. Hwang, S. Khan, S. Loibl, E. Morris, Alejandra T. Perez, M. Regan, P. Spears, Preeti K. Sudheendra, W. Symmans, R. Yung, Brittany E. Harvey, D. Hershman   +16 more
semanticscholar   +1 more source